Newsfeeds - Spark Newswire

1 minute read

Oppenheimer Initiates Coverage On Biomea Fusion with Outperform Rating, Announces Price Target of $22

Today, 8:05 AM

Oppenheimer analyst Hartaj Singh initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Outperform rating and announces Price Target of $22.

BMEA

4 minute read

Biomea Fusion Publishes Abstract For BMF-219 At American Society Of Hematology

By Benzinga Newsdesk

Today, 8:05 AM

BMF-219 displays global disruption of menin, highlighting ‘219’s novel mechanism of action Molecule elicits broad impact on the complexes surrounding menin, resulting in strong modulation of MYC

BMEA

6 minute read

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs

By Shanthi Rexaline

Today, 8:05 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)

ABEO

1 minute read

Biomea Fusion To Start Early-Stage Leukemia Setting Trial With BMF-219

By Vandana Singh

Today, 8:05 AM

The FDA has signed off Biomea Fusion Inc’s (NASDAQ:BMEA) Investigational New Drug application to begin a Phase 1 trial of BMF-219,…

BMEA

2 minute read

FDA
News

Biomea Fusion Announces FDA Clearance Of Investigational New Drug Application For Irreversible Menin Inhibitor BMF-219

By Benzinga Newsdesk

Today, 8:05 AM

Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, today

BMEA

2 minute read

4 Stocks Insiders Are Buying

By Lisa Levin

Today, 8:05 AM

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

BMEA

5 minute read

60 Biggest Movers From Yesterday

By Lisa Levin

Today, 8:05 AM

Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion.

ABVC

3 minute read

The Past Week’s Notable Insider Buys Included AppLovin, Cricut, Biotechs And More

By Nelson Hem

Today, 8:05 AM

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders were making return trips to the buy window last week. Insider buying was also happening in the wake of recent earnings reports.

AMEH